Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20343438 | 0.83 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA7ALDH1A1KDM4E | |
| SCHEMBL20343404 | 0.83 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA7ALDH1A1KDM4E | |
| SCHEMBL29615784 | 0.81 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA7ALDH1A1KDM4E | |
| SCHEMBL653224 | 0.80 | FUCA1 (0.55) | — | |
| SCHEMBL477142 | 0.80 | FUCA1 (0.55) | — | |
| Hydrochloric Acid SCHEMBL3018917 | 0.78 | FUCA1 (0.53) | — | |
| Hydrochloric Acid SCHEMBL2264027 | 0.78 | FUCA1 (0.53) | — | |
| SCHEMBL21238460 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA7MAPK1ALDH1A1 | |
| SCHEMBL12744595 | 0.77 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL16026435 | 0.76 | CHRNB2 (0.85) | CHRNB2CHRNA4ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | CHRNB2 3875/4885CHRNA4 3227/4885CHRNA7 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.